This document is intended to provide communication to updated Regulations Regarding Fees Payable in Terms of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965) have been gazetted on 12 February 2025 introducing a new fee dispensation....
This document is intended to provide communication on the revised Regulation Regarding Fees Payable in Terms of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965)....
Attn: Board/Committee Members/Evaluators: Please take note of the dates for submission of claims for the remainder of the 2024/25 financial year....
The SAHPRA fees that have been gazetted are implementable from 22 December 2020. The fees outlined in most cases are self-explanatory, however in the case of fees payable for technical amendments related to quality, there are several options listed which require clarity and hence the...
Payment of retention fees for the year ending 31 March 2024 in respect of medicines and/or various licences registered until 31 December 2023....
Your attention is drawn to the provisions of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) as amended, making provision for the payment of retention fees to the Regulatory Authority in respect of medicines, medical devices and IVDs registered and site licences...
Payment of Retention Fees for the Financial Year Ending 31 March 2022 in Respect of Medicines Registered Up and Until 31 December 2020 and/or Manufacture or Wholesale Licences...
This document is intended to provide communication to the Medical Device Establishment Licence Industry in relation to the Appointment of Yellow Clip Financial Services....
Your attention is drawn to the provisions of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) as amended, making provision for the payment of retention fees to the Regulatory Authority in respect of medicines, medical devices and IVDs registered and site licences...